By / September 14, 2020

Tropizen expands in Puerto Rico to tackle sharp increase in demand for cannabis

The development of medicinal cannabis in Puerto Rico has been surging in the past month, adopting new users every day which has led to a sharp increase in demand for cannabis. In order to tackle this issue, the cannabis firm ‘Tropizen’ will start dealing with the shortage of cannabis on the island by increasing its crops by 400 percent in the coming months.

It is worth mentioning that the sale of medicinal cannabis products is an important part of the general demand as they represent an average of 20 percent of the market, in terms of sales to dispensaries.

Explaining their plans, Tropizen announced the successful cultivation of its first cannabis crop at its new outdoor growing facility. It will be used for the sale of cannabis to authorized dispensaries and the manufacture of cannabis-infused products.

If you want to know more about cannabis, how Tropizen is tackling the cannabis shortage in Puerto Rico, and to find out the latest cannabis news, download the mobile application.

Tropizen will focus on production as supply fails to meet consumers’ needs

“This harvest represents an important milestone for our company as we continue to expand to meet patient demand for high-quality cannabis” said Tropizen co-founder Marni Meistrell. We grow our cannabis near the base of the El Yunque rainforest, following industry best practices as we research and test new strains that can flourish in this location”.

To that end, the company will add 7,000 square feet (650 square meters) of outdoor grow space to the 10,000 just completed before the end of this year, Meistrell said.

Tropizen’s increase in cannabis production capacity by 400 percent was accomplished with an investment of more than $ 1 million. Moreover, the new cannabis crops are made up of five of the company’s best performing strains, which will help to solidify their position of high-quality cannabis producers.

The firm alternates cultivation between five primary and five secondary strains, including ‘Brian Berry Cough’, ‘Ogiesel’ and ‘Agent Orange’, all exclusive to the company in Puerto Rico. One of the company’s priorities is to grow rare tropical strains as part of the research and development processes.

Also, the company will introduce a new product that will be more accessible in price but with the same medicinal effectiveness as the “premium” one.

Tropizen has become a key company in Puerto Rico’s cannabis sector

Tropizen became the first grower on the island to offer cannabis dispensaries individually packaged, rather than in bulk which allow them to generate higher sales volume. Also, patients get a fresher product as the packaging protects the cannabis from exposure to degrading conditions, including oxygen and moisture.

Presently, the prepackaged cannabis represents 20 percent of sales to dispensaries. Tropizen offers product consistency, exceptional plant genetics and attention to detail, according to Novacann Labs COO Christian Burgos.

“Normally we see that quality suffers when production volume increases, however, that has not been our experience with Tropizen. Also, the results of their harvest show strict compliance and consistent quality control,” explained Burgos.

The trend in the industry has been to use living soil with beneficial insects and organic processes in its cultivation facilities. An outside entomologist serves as a technical advisor and conducts weekly inspections of the plants. And most importantly, no chemical pesticides are used during the cultivation process.

Finally, Meistrell pointed out that this summer the cannabis flower has been scarce.

“Dispensaries are consistently running out of product even though our production volume has increased. It seems that we are approaching a worrying scenario where patients would have greater difficulty in obtaining their medicine, leading to an increase in prices”, he mentioned.

Experts believe the growth of patients on the island could be a determining factor in the increasing demand for cannabis but no official figures have been published this year.


(Featured image by Ryan Ancill Shulman via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in La Marihuana, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.